VIP — Vasoactive Intestinal Peptide — was discovered in 1969 by Sami Said and Viktor Mutt, who isolated it from porcine lung and intestinal tissue and observed that it dilated blood vessels. The name stuck. It is now one of the least accurate names in the entire field of peptide biology.
VIP is expressed throughout the central nervous system, enteric nervous system, thymus, lung tissue, and immune organs. It is produced by neurons, epithelial cells, and immune cells. It belongs to the secretin-glucagon superfamily alongside PACAP (pituitary adenylate cyclase-activating peptide), sharing structural homology that hints at deep evolutionary conservation — VIP sequences are highly similar across animals from fish to humans, suggesting the molecule is performing something fundamentally important.
The modern understanding of VIP is as an immune tolerance orchestrator: it programs dendritic cells to generate regulatory T cells rather than inflammatory ones, shifts macrophages from inflammatory to reparative states, maintains gut barrier integrity, and synchronises circadian clocks across the nervous system. The vasodilator identity that gave it its name is real but peripheral to its actual significance.
Why the name is misleading: VIP was named for its vasodilatory effects observed in the first isolation experiments in 1969. Subsequent decades of research revealed that vasodilation is probably the least important thing VIP does. It operates as a master immune tolerance signal — the key difference between "fire extinguisher" (VPAC1 — acute anti-inflammation) and "architect" (VPAC2 — long-term tolerance programming). The naming conventions of endocrinology freeze to the first observed function, regardless of what the molecule is actually for.
VIP's mechanism is defined by its two receptor subtypes, which serve fundamentally different functions and express at different times during immune activation. Understanding this distinction explains why VIP is being studied for chronic inflammatory conditions rather than just acute inflammation.
VIP's community use is quite different from most peptides in this book. It is not primarily a performance or longevity compound — it is used almost exclusively in the context of Chronic Inflammatory Response Syndrome (CIRS), also known as mold illness or biotoxin illness. The Shoemaker Protocol — a staged treatment approach for CIRS developed by Dr. Ritchie Shoemaker — uses intranasal VIP as the final step of treatment once other markers are normalised.
In this context, VIP has a clear and specific role: restoring immune regulation in people whose immune systems have become chronically activated following biotoxin exposure. The community for VIP is therefore not the general biohacking community but a specific subset dealing with CIRS — and their reports are consistently positive in this narrow application.
VIP is a potent anti-inflammatory neuropeptide that modulates the immune system bidirectionally. Synergies focus on supporting the anti-inflammatory and immune regulatory pathways VIP uses.
Disclaimer: These recommendations are educational and based on the known mechanisms of each compound. Individual responses vary. Consult a qualified healthcare provider before changing your supplement or exercise regimen, particularly when using experimental peptides.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
VIP is one of the most scientifically interesting peptides in this book — and one of the most context-dependent. The receptor biology is genuinely sophisticated and the immune tolerance orchestration concept is far more mechanistically coherent than most peptide applications. It has real Phase 3 trial data (for respiratory applications), real anti-inflammatory mechanisms confirmed across decades of research, and a specific clinical niche in CIRS treatment that is coherent and apparently effective in that narrow context.
The broader application challenges are real. The rapid degradation makes delivery difficult. The vasodilation limits systemic dosing. The immune tolerance effects that make it valuable in CIRS may be counterproductive in healthy individuals with normal immune function. And outside the CIRS and pulmonary applications, the human data is limited.
For someone with CIRS being managed by a Shoemaker Protocol clinician: VIP has a well-defined role with reasonable mechanistic support. For healthy adults seeking general immune optimisation: the evidence base and risk-benefit calculation is much less clear.